Forest seeks FDA approval of depression product

Forest Laboratories Inc. (NYSE:FRX) submitted an NDA to FDA for levomilnacipran to treat major depressive disorder (MDD) in adults. Forest has exclusive rights to develop and commercialize the selecti...